These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
269 related articles for article (PubMed ID: 27600596)
1. The dopamine D3 receptor, a quarter century later. Sokoloff P; Le Foll B Eur J Neurosci; 2017 Jan; 45(1):2-19. PubMed ID: 27600596 [TBL] [Abstract][Full Text] [Related]
2. Binding of the D3-preferring antipsychotic candidate F17464 to dopamine D3 and D2 receptors: a PET study in healthy subjects with [ Slifstein M; Abi-Dargham A; Girgis RR; Suckow RF; Cooper TB; Divgi CR; Sokoloff P; Leriche L; Carberry P; Oya S; Joseph SK; Guiraud M; Montagne A; Brunner V; Gaudoux F; Tonner F Psychopharmacology (Berl); 2020 Feb; 237(2):519-527. PubMed ID: 31773210 [TBL] [Abstract][Full Text] [Related]
3. Occupancy of brain dopamine D3 receptors and drug craving: a translational approach. Mugnaini M; Iavarone L; Cavallini P; Griffante C; Oliosi B; Savoia C; Beaver J; Rabiner EA; Micheli F; Heidbreder C; Andorn A; Merlo Pich E; Bani M Neuropsychopharmacology; 2013 Jan; 38(2):302-12. PubMed ID: 22968817 [TBL] [Abstract][Full Text] [Related]
5. Imaging the D3 dopamine receptor across behavioral and drug addictions: Positron emission tomography studies with [(11)C]-(+)-PHNO. Boileau I; Nakajima S; Payer D Eur Neuropsychopharmacol; 2015 Sep; 25(9):1410-20. PubMed ID: 26141509 [TBL] [Abstract][Full Text] [Related]
6. Dopamine (D2/3) receptor agonist positron emission tomography radiotracer [11C]-(+)-PHNO is a D3 receptor preferring agonist in vivo. Narendran R; Slifstein M; Guillin O; Hwang Y; Hwang DR; Scher E; Reeder S; Rabiner E; Laruelle M Synapse; 2006 Dec; 60(7):485-95. PubMed ID: 16952157 [TBL] [Abstract][Full Text] [Related]
7. Selective antagonism at dopamine D3 receptors as a target for drug addiction pharmacotherapy: a review of preclinical evidence. Heidbreder C CNS Neurol Disord Drug Targets; 2008 Nov; 7(5):410-21. PubMed ID: 19128200 [TBL] [Abstract][Full Text] [Related]
8. Imaging dopamine D3 receptors in the human brain with positron emission tomography, [11C]PHNO, and a selective D3 receptor antagonist. Searle G; Beaver JD; Comley RA; Bani M; Tziortzi A; Slifstein M; Mugnaini M; Griffante C; Wilson AA; Merlo-Pich E; Houle S; Gunn R; Rabiner EA; Laruelle M Biol Psychiatry; 2010 Aug; 68(4):392-9. PubMed ID: 20599188 [TBL] [Abstract][Full Text] [Related]
10. Dopamine D3 receptor ligands for drug addiction treatment: update on recent findings. Le Foll B; Collo G; Rabiner EA; Boileau I; Merlo Pich E; Sokoloff P Prog Brain Res; 2014; 211():255-75. PubMed ID: 24968784 [TBL] [Abstract][Full Text] [Related]
11. Dopamine D3 as well as D2 receptor ligands attenuate the cue-induced cocaine-seeking in a relapse model in rats. Gál K; Gyertyán I Drug Alcohol Depend; 2006 Jan; 81(1):63-70. PubMed ID: 16005579 [TBL] [Abstract][Full Text] [Related]
12. Blockade of [11C](+)-PHNO binding in human subjects by the dopamine D3 receptor antagonist ABT-925. Graff-Guerrero A; Redden L; Abi-Saab W; Katz DA; Houle S; Barsoum P; Bhathena A; Palaparthy R; Saltarelli MD; Kapur S Int J Neuropsychopharmacol; 2010 Apr; 13(3):273-87. PubMed ID: 19751545 [TBL] [Abstract][Full Text] [Related]
13. In vivo quantification of regional dopamine-D3 receptor binding potential of (+)-PHNO: Studies in non-human primates and transgenic mice. Rabiner EA; Slifstein M; Nobrega J; Plisson C; Huiban M; Raymond R; Diwan M; Wilson AA; McCormick P; Gentile G; Gunn RN; Laruelle MA Synapse; 2009 Sep; 63(9):782-93. PubMed ID: 19489048 [TBL] [Abstract][Full Text] [Related]
14. Occupancy of Dopamine D3 and D2 Receptors by Buspirone: A [11C]-(+)-PHNO PET Study in Humans. Le Foll B; Payer D; Di Ciano P; Guranda M; Nakajima S; Tong J; Mansouri E; Wilson AA; Houle S; Meyer JH; Graff-Guerrero A; Boileau I Neuropsychopharmacology; 2016 Jan; 41(2):529-37. PubMed ID: 26089182 [TBL] [Abstract][Full Text] [Related]
15. Pharmacology profile of F17464, a dopamine D Cosi C; Martel JC; Auclair AL; Collo G; Cavalleri L; Heusler P; Leriche L; Gaudoux F; Sokoloff P; Moser PC; Gatti-McArthur S Eur J Pharmacol; 2021 Jan; 890():173635. PubMed ID: 33065094 [TBL] [Abstract][Full Text] [Related]
16. Dopamine D2 and D3 receptor occupancy in normal humans treated with the antipsychotic drug aripiprazole (OPC 14597): a study using positron emission tomography and [11C]raclopride. Yokoi F; Gründer G; Biziere K; Stephane M; Dogan AS; Dannals RF; Ravert H; Suri A; Bramer S; Wong DF Neuropsychopharmacology; 2002 Aug; 27(2):248-59. PubMed ID: 12093598 [TBL] [Abstract][Full Text] [Related]
17. What is the role of the D3 receptor in addiction? A mini review of PET studies with [(11)C]-(+)-PHNO. Payer D; Balasubramaniam G; Boileau I Prog Neuropsychopharmacol Biol Psychiatry; 2014 Jul; 52():4-8. PubMed ID: 23999545 [TBL] [Abstract][Full Text] [Related]
18. Acutely administered antipsychotic drugs are highly selective for dopamine D2 over D3 receptors. McCormick PN; Wilson VS; Wilson AA; Remington GJ Pharmacol Res; 2013 Apr; 70(1):66-71. PubMed ID: 23327779 [TBL] [Abstract][Full Text] [Related]
19. [¹¹C]-(+)-PHNO PET imaging of dopamine D(2/3) receptors in Parkinson's disease with impulse control disorders. Payer DE; Guttman M; Kish SJ; Tong J; Strafella A; Zack M; Adams JR; Rusjan P; Houle S; Furukawa Y; Wilson AA; Boileau I Mov Disord; 2015 Feb; 30(2):160-6. PubMed ID: 25641350 [TBL] [Abstract][Full Text] [Related]
20. Neuronal circuitry underlying the impact of D3 receptor ligands in drug addiction. Le Foll B; Di Ciano P Eur Neuropsychopharmacol; 2015 Sep; 25(9):1401-9. PubMed ID: 25266821 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]